Skip to main content

Table 3 Multivariate analysis of the association between HCMV seropositivity and ESS progression during RA, study of ESPOIR cohort

From: Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients

Erosion Sharp score (baseline–1 year) score Δ > 1

Odds ratio

Standard error

z

P > lzl

[95% conf. interval]

Erosion Sharp score at baseline

5.3180

1.9356

4.59

0.000

2.6057

10.854

ACPA+

5.1915

1.7635

4.85

0.000

2.6677

10.103

HCMV

0.5255

0.1505

− 2.25

0.025

0.2998

0.9213

Cumulated dose of glucocorticoids

0.9997

0.0001

− 2.29

0.022

0.9995

1

Use of csDMARDs

1.7987

1.0696

0.99

0.324

0.5608

5.7694

Use of bDMARDs

1.3298

0.9829

0.39

0.700

0.3123

5.6619